Mar 10, 2023

Canada's Largest Bank Sees 60% Upside In This Psychedelic Stock

Subscribe to Excellence
Welcome aboard! Your submission has been received and you are now a member of the community.
Oops! Something went wrong while submitting the form. Please check the format of your entry.

MindMed (Nasdaq: MNMD) (NEO: MMED) (DE: MMQ) (the “Company”) is an industry-leading biotech company engineering psychedelic-inspired therapies. The company is developing a combinatorial approach to treating mental illnesses with hallucinogenic (e.g., LSD) and non-hallucinogenic (aka “microdosing”) therapies in clinical settings. MindMed's core philosophy is that a coordinated effort between therapists, drug developers, and patients is needed to develop personalized, precision treatments on a patient-by-patient basis.


The company has multiple drug assets spanning classic psychedelic molecules (such as psilocybin and DMT), 2nd generation psychedelic variants with enhanced pharmacology, and 3rd generation new chemical entities (NCEs) that leverage the core mechanism of action of classic psychedelics but have enhanced functionality. These developmental assets are being pursued into clinical trials against indications such as General Anxiety Disorder (GAD), substance abuse, autism, Major Depressive Disorder (MDD), and cluster headaches. MindMed is leading the development of LSD as a treatment for anxiety disorders with their ongoing Phase 2b study.

Clinical efficacy

MM-120 (LSD analog)

MM-402 (MDMA analog)

Upcoming catalysts

  • MM-120 Phase 2b (GAD) readout late 2023
  • MM-120 Phase 2a (ADHD) readout late 2023
  • MM-402 Phase 1 study to initiate in 2023

Daily (MNMD)

MNMD is deeply oversold, at important support, and currently trading ~20% below its Book Value per share. This morning, RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $5 price target on Mind Medicine shares. The upcoming Phase 2a and Phase 2b readouts for lead drug candidate MM-120 will force a re-rating of this stock. We added to our MNMD long position this week in light of the deep discount to what we believe to be the intrinsic value of the company and the strong chart support near $3 per share.

MindMed has expected cash runway through clinical readouts into 2025.

Mind Medicine is participating in two investor conferences on Monday afternoon:


Author owns shares of MindMed at the time of publishing and may choose to buy or sell at any time without notice.


The work included in this article is based on current events, technical charts, company news releases, and the author’s opinions. It may contain errors, and you shouldn’t make any investment decision based solely on what you read here. This publication contains forward-looking statements, including but not limited to comments regarding predictions and projections. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. This publication is provided for informational and entertainment purposes only and is not a recommendation to buy or sell any security. Always thoroughly do your own due diligence and talk to a licensed investment adviser prior to making any investment decisions. Junior resource and biotechnology companies can easily lose 100% of their value so read company profiles on for important risk disclosures. It’s your money and your responsibility.